Ku P K, Tong M C, Lo P, van Hasselt C A
Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong SAR.
Am J Otol. 2000 Jan;21(1):24-7.
To assess the efficacy and safety of intravenous ondansetron (4 mg) for the prevention of nausea and vomiting after middle ear surgery under local anesthesia.
The study was conducted by Division of Otorhinolaryngology in Prince of Wales Hospital, which is a tertiary referral center and teaching hospital for The Chinese University of Hong Kong.
A double-blind randomized controlled trial.
Fifty-eight Chinese patients undergoing tympanoplasty under local anesthesia from July 1995 to June 1997 were recruited. The mean age of patients was 42.8 years (range 18-71 years).
Patients were randomly allocated to receive a single dose of intravenous ondansetron (4 mg) (n = 29) or placebo (n = 29) immediately before surgery.
Patients were assessed for severity and frequency of postoperative nausea and vomiting at the 1st, 2nd, 4th, 8th, and 24th hours after middle ear surgery.
Female patients showed a higher prevalence of postoperative nausea and vomiting. Twenty-eight percent of the patients experienced postoperative nausea, of whom 14% also experienced vomiting. Although the ondansetron group demonstrated a lower prevalence of postoperative nausea and vomiting (PONV) (24% nausea and 10% vomiting) than the placebo group (31% nausea and 17% vomiting), significant reduction in postoperative vomiting only occurred in the first postoperative hour (p = 0.038). No complications or adverse side effects were found to be associated with the use of ondansetron.
Single-dose ondansetron (4 mg) given intravenously preoperatively significantly reduces postoperative vomiting in patients after tympanoplasty under local anesthesia and causes no adverse effects.
评估静脉注射昂丹司琼(4毫克)预防局部麻醉下中耳手术后恶心和呕吐的疗效及安全性。
该研究由威尔士亲王医院耳鼻喉科进行,威尔士亲王医院是香港中文大学的三级转诊中心和教学医院。
双盲随机对照试验。
招募了1995年7月至1997年6月期间接受局部麻醉下行鼓室成形术的58名中国患者。患者的平均年龄为42.8岁(范围18 - 71岁)。
患者在手术前即刻被随机分配接受单剂量静脉注射昂丹司琼(4毫克)(n = 29)或安慰剂(n = 29)。
在中耳手术后第1、2、4、8和24小时评估患者术后恶心和呕吐的严重程度及频率。
女性患者术后恶心和呕吐的发生率较高。28%的患者出现术后恶心,其中14%的患者还出现呕吐。尽管昂丹司琼组术后恶心和呕吐(PONV)的发生率(恶心24%,呕吐10%)低于安慰剂组(恶心31%,呕吐17%),但仅在术后第一小时术后呕吐有显著减少(p = 0.038)。未发现使用昂丹司琼有并发症或不良副作用。
术前静脉注射单剂量昂丹司琼(4毫克)可显著降低局部麻醉下鼓室成形术后患者的术后呕吐,且无不良反应。